



Discontinuation Notice

Due to global manufacturing constraints, formulary losses impacting patient access, and the availability of alternative options, **Novo Nordisk will be discontinuing Levemir®** in the U.S. We will continue to provide Levemir® FlexPen® and Levemir® vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected.

- **Mid-January 2024:** Supply disruptions of Levemir® FlexPen®
- **April 1, 2024:** Discontinuation of Levemir® FlexPen®
- **December 31, 2024:** Full brand discontinuation, including Levemir® vial

Our top priority is always the health and safety of the patients that use our products. We made this decision after careful consideration, and are confident that patients will be able to access alternative treatments in the U.S.

We recommend that healthcare providers talk to their patients about alternative treatment options in advance of this supply disruption and discontinuation to ensure continuity of care.

<https://www.novomedlink.com/diabetes/products/treatments/levemir.html>